Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study

Date
2014
Author
van Laar, Teus
Burn, David
Micheli, Federico
Storch, Alexander
Emre, Murat
Poewe, Werner
De Deyn, Peter Paul
Barone, Paolo
Kulisevsky, Jaime
Pourcher, Emmanuelle
Strohmaier, Christine
Tenenbaum, Nadia
Callegari, Francesca
Pahwa, Rajesh
Durif, Frank
Metadata
Show full item record
Abstract
Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.
URI
http://hdl.handle.net/20.500.12627/106582
https://doi.org/10.1097/wnf.0000000000000010
Collections